The social value of innovation

EJHP Practice

Volumn 16, Issue 3, 2010, Pages 70-73

  Rutten, Frans F H ^a   Vulto, Arnold G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTHORITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EUROPE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH SERVICE; LONGEVITY; MEDICAL TECHNOLOGY; QUALITY ADJUSTED LIFE YEAR; SOCIAL PSYCHOLOGY;

EID: 77957153932     PISSN: 17819989     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (8)

1. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Affairs. 2001;20(5):11-29.
2. Lichtenberg F. Benefits and costs of newer drugs: an update. Cambridge, US: National Bureau of Economic Research; June 2002.
3. Lichtenberg F. Why has longevity increased more in some states than in others? The role of medical innovation and others. Medical Progress Report No 4; 2007.
4. Santerre RE. The new drug offset effect: some national and international evidence. Connecticut: MPRA; 2009.
5. Busse R, Schreyögg J. Defining the health benefit baskets in Europe - nine European countries in comparison. European Journal of Health Economics. 2005;6(1):S1-72.
6. Baker R, Chilton S, Donaldson C, Jones-Lee M, Metcalf H, Shackley P, Ryan M. Determining the societal value of a QALY by surveying the public in England and Wales: a research protocol. Submission to NICE.
7. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality- adjusted life year: in search of a standard. Medical Decision Making. 2000;20: 332-42.
8. Le Fanu J. The rise and fall of modern medicine. New York: Carroll & Graf Publishers; 1999.